VPD/RMPRU

11th Floor Central West Wing

Nurses Residence

Chris Hani Baragwanath Hospital

Diepkloof, Soweto

Phone: 011 983 4260

Fax: 086 646 4208

E-mail: siwei@rmpru.co.za

2007


54. Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25: 2451-7.

55. Madhi SA, Klugman KP Sensitivity of “radiographically confirmed pneumonia” in measuring the burden of pneumococcal pneumonia prevented by conjugate pneumococcal vaccines: Is there space for improvement? Vaccine 2007; 25: 2413-9.

56. Madhi SA, Ludewick H, Kuwanda L, van Niekerk N, Cutland C, Klugman KP. Epidemiology of severe human metapneumovirus lower respiratory tract infection in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediar Infect Dis J. 2007; 26: 693-9.

57. Siber GR, Chang I, Baker S, Fernsten P, Kate O’Brien K, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R. Estimating the Protective Concentration of Anti-Pneumococcal Capsular Polysaccharide Antibodies. Vaccine. 2007; 25: 3 816-26.

58. Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected children. J Infect Dis. 2007; 196: 1 662-6.

59. Albrich WC, Madhi SA, Lafond KE, Klugman KP. Herd immunity after pneumococcal conjugate vaccination. Lancet. 2007; 370: 218-9.

60. Klugman KP, Madhi SA, Feldman C. HIV and Pneumococcal Disease.  Curr Opin Infect Dis 2007; 20: 11-15.

61. Klugman KP, Madhi SA. Pneumococcal vaccines and flu preparedness. Science 2007; 316: 49-50.


2008


62. Cooper PA, Madhi SA, Huebner RE, Mbelle N, Abdool Karim SS, Kleinschmidt I,   Forrest BD, Klugman KP. Apnea and its possible relationship to immunization in ex-premature infants. Vaccine 2008; 26: 3410-3.

63.  Edginton ME, Rakgokong L, Verver S, Madhi SA, Koornhof  HJ, Wong ML, Hodkinson HJ. Tuberculosis culture testing at a tertiary care hospital: options for improved management and use for treatment decisions. Int J Tuberc Lung Dis. 2008; 12: 786-91.

64. Zar HJ, Madhi SA. Pneumococcal conjugate vaccine: A health priority. S Afr  Med J 2008 June

65. Green RJ, Feldman C, Schoub B, Richards GA, Madhi SA, Zar HJ, Lalloo U. Influenza guideline for South Africa- update 2008. S Afr Med J  2008; 98: 224-30.

66.  Madhi SA, Levine OS; Hajjeh R, Mansoor OD, Cherian T.  Vaccines to   prevent pneumonia and improve child survival. Bulletin of WHO 2008; 86: 365-372 .

67. Madhi SA, Whitney C, Nohynek H. Lessons learned from Clinical Trials Evaluating Pneumococcal Conjugate Vaccine Efficacy against Pneumonia and Invasive Disease. Vaccine, 2008; 26, (Suppl 2), B9-B15.

68. Klugman KP, Madhi SA, Albrich W.  Novel approaches to the diagnosis of Streptococcus pneumoniae as a cause of community acquired pneumonia. Clin Infect Dis. 2008; 47 (Suppl 3) S202-6.

69. Madhi SA, Schoub B, Klugman KP. Interaction between influenza virus and Streptococcus pneumoniae in the aetiology of severe pneumonia. Expert Review of Respiratory Medicine 2008; 2; 663-672.

70. Zar H, Madhi SA. Pneumococcal conjugate vaccine- advancing child health in South Africa.  South African Journal of Child Health. 2008; 2: 94-95.    

71. du Plessis M, von Gottberg A, Madhi SA, Hattingh O, de Gouveia L, Klugman KP for  the Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). Prevalence of serotype 6C among invasive pneumococcal

       isolates previously identified as serotype 6A in South Africa. Int J Antimicrob Agents 2008 : 32S; S66–S70.

72.  Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Madhi SA, Jean-Philippe P and McIntyre J on behalf of the CHER Study Team. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Trial. New Eng J Med 2008; 359:2233-44.

<<<<<<Back to Publications